AVROBIO Inc (AVRO) News, Price and Chart - FAWS

Your browser has either disabled or does not support javascript. Javascript is required for full website experience.

Thu May 6th, 2021

- 17:49
  Press ReleasesONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the FirmPR Newswire

Mon May 3rd, 2021

- 13:42
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene TherapyBenzinga

Tue March 2nd, 2021

- 12:41
  AnalysisAvrobio started at hold with $14 stock price target at Stifel NicolausMarketWatch

Mon March 1st, 2021

- 16:56
  Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In EuropeBenzinga

Thu February 18th, 2021

- 00:11
  AnalysisAvrobio: An Update After Stock Price Drop After bluebird Trial HaltSeeking Alpha

Fri February 12th, 2021

- 10:48
  AnalysisAVROBIO (AVRO) Presents At 17th Annual Virtual WORLDSymposium 2021 - SlideshowSeeking Alpha

Sat December 26th, 2020

- 10:01
  AnalysisAvrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 CatalystsSeeking Alpha

Fri December 25th, 2020

- 15:00
  AnalysisAVROBIO: Undercovered Gene Therapy Developer With Excellent PromiseSeeking Alpha

Thu October 1st, 2020

- 06:54
  AnalysisProtalix Could Claim Substantial Global Market Share In Fabry DiseaseSeeking Alpha

Mon September 14th, 2020

- 17:51
  AnalysisAVROBIO (AVRO) Presents At 18th Annual Global Healthcare Virtual Conference - SlideshowSeeking Alpha

Fri September 11th, 2020

- 14:56
  AnalysisAVROBIO (AVRO) Investor Presentation - SlideshowSeeking Alpha

Thu August 13th, 2020

- 22:02
  AnalysisAVROBIO (AVRO) Presents At 2020 Wedbush PacGrow Healthcare Conference - SlideshowSeeking Alpha

SPY$395.63-6.2%

QQQ$315.85-8.5%

DOW$64.140.94%

NVAX$173.01-3.8%

SPY$395.63-6.2%

QQQ$315.85-8.5%

DOW$64.140.94%

NVAX$173.01-3.8%

About Developer Contact